# Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia

> **NCT00485901** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 50 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Olanzapine Hydrochloride
- **DRUG:** Haloperidol

## Key facts

- **NCT ID:** NCT00485901
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** 2005-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2007-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00485901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00485901, "Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00485901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*